Ophthotech Corp CFO Bruce Peacock Sells 6,191 Shares (OPHT)
Ophthotech Corp (NASDAQ:OPHT) CFO Bruce Peacock sold 6,191 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $37.78, for a total transaction of $233,895.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
OPHT has been the subject of a number of recent research reports. Analysts at Gabelli initiated coverage on shares of Ophthotech Corp in a research note on Friday, July 25th. They set a “buy” rating and a $40.00 price target on the stock. Separately, analysts at Goldman Sachs initiated coverage on shares of Ophthotech Corp in a research note on Friday, July 25th. They set a “neutral” rating and a $44.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Ophthotech Corp from $45.00 to $61.00 in a research note on Thursday, July 17th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $64.00.
Ophthotech Corp (NASDAQ:OPHT) traded up 0.71% on Monday, hitting $38.52. The stock had a trading volume of 213,511 shares. Ophthotech Corp has a one year low of $22.61 and a one year high of $47.99. The stock has a 50-day moving average of $41.17 and a 200-day moving average of $36.33. The company’s market cap is $1.284 billion.
Ophthotech Corp (NASDAQ:OPHT) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.03. Analysts expect that Ophthotech Corp will post $-2.19 EPS for the current fiscal year.
Ophthotech Corporation is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye.
Receive News & Ratings for Ophthotech Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.